Sunday, September 27, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 2, 2026

AI in Clinical Trials Market Research 2026: Market to Reach $18.62 Billion by 2040 with IQVIA, Medidata, IBM Watson, Oracle, and Phesi Leading Through Integrated Data and Patient Matching Platforms

View original at globenewswire.com
AI in Clinical Trials Market Research 2026: Market to Reach $18.62 Billion by 2040 with IQVIA, Medidata, IBM Watson, Oracle, and Phesi Leading Through Integrated Data and Patient Matching Platforms Dublin, March 02, 2026 (GLOBE NEWSWIRE) -- The "AI in Clinical Trials Market, till 2040: Distribution by Trial Phase, Targ…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Clinical trials consume roughly 50-70% of drug development timeline and budget

    80% confidence

  • Asia-Pacific currently captures a significant share of the AI in clinical trials market due to massive, diverse patient population and cost-effective operations

    80% confidence

  • Many clinical trials fail due to design flaws, recruitment issues, stratification errors, and high dropout rates

    80% confidence

  • Oncological disorders currently capture majority share of the AI in clinical trials market due to high volume and complexity of cancer trials

    80% confidence

  • Developing novel therapeutic interventions typically spans about 10-15 years

    80% confidence

  • Generative AI can potentially cut drug development time by 50% and costs by 25%

    80% confidence

  • The global artificial intelligence in clinical trials market size is estimated to grow from USD 2.09 billion in 2026 to USD 18.62 billion by 2040, at a CAGR of 17.0%

    80% confidence

  • Digital twins enable smaller clinical trials with higher statistical power by simulating individual patient responses

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com